Die Meldepflichten im Außenwirtschaftsrecht bedeuten für Unternehmen und Privatpersonen häufig einen hohen bürokratischen Aufwand. Umso erfreulicher sind die Neuerungen und Klarstellungen, die seit dem 1. Januar 2025 gelten: Zum Beispiel wurden die Meldeschwellen deutlich angehoben und Meldefristen vereinheitlicht. Außerdem stellt die Außenwirtschaftsverordnung (AWV) nun klar, dass auch die Übertragung von Kryptowerten bei Erreichen der Schwellenwerte eine meldepflichtigte Zahlung darstellt; zudem wurden neue Kennzahlen für Kryptowerte eingeführt. Wir fassen die relevanten Neuerungen zusammen.

With the 15th amendment of the Foreign Trade and Payments Ordinance (AWV), the Federal Ministry for Economic Affairs and Energy will soon extend its control over acquisitions of German companies by EU foreign companies. The amendment is perceived as the Federal Government’s direct reaction to the COVID-19 crisis, due to its concern in large part to protect the healthcare sector. The case of the Tübingen-based company CureVac, involving a US purchaser and raising the question of the right of prohibition, may have also contributed to this development. The 16th amendment to the AWV is expected to comprehensively expand and adapt investment control in foreign trade law. It is aimed at uniformly implementing Regulation (EU) 2019/452 (*_EU Screening Regulation*_), which came into force in April 2019, and the amendment to the Foreign Trade and Payments Act (AWG) adopted already by the Cabinet on 8th April 2020. Since the latter remains under discussion in the committees of the Bundestag, the Federal Ministry for Economic Affairs and Energy has brought forward what it considers to be particularly urgent adjustments.

27 March 2020
The current Covid 19 pandemic has long since developed into an economic crisis, the full impact of which cannot yet be predicted. The crisis also affects those companies that are active in so-called systemically important areas and whose commitment is particularly important for the protection of public health. In the opinion of the EU Commission, it is therefore particularly important to prevent a “sell-out” of companies and technologies that are critical and key to the health sector.